Treatment of HIV-associated non-Hodgkin lymphoma with rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide resulted in high complete remission and 2-year failure-free and overall survival rates but a high rate of infection.
CITATION STYLE
Straus, D. J. (2005, March 1). HIV-associated lymphoma: Promising new results, but with toxicity. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2004-12-4729
Mendeley helps you to discover research relevant for your work.